[{"id":"a652e199-25c7-474e-ae48-fce734badcf9","acronym":"","url":"https://clinicaltrials.gov/study/NCT03579875","created_at":"2021-01-18T17:36:44.603Z","updated_at":"2024-07-02T16:34:37.677Z","phase":"Phase 2","brief_title":"Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders","source_id_and_acronym":"NCT03579875","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • Campath (alemtuzumab) • melphalan • fludarabine IV • busulfan • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 11/13/2018","start_date":" 11/13/2018","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/05/2029","study_completion_date":" 01/05/2029","last_update_posted":"2024-06-06"},{"id":"c6fc72ec-918c-4d87-82e5-708aa1f2978a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01361711","created_at":"2021-01-18T05:34:18.032Z","updated_at":"2025-02-25T13:16:51.580Z","phase":"Phase 2","brief_title":"Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia","source_id_and_acronym":"NCT01361711","lead_sponsor":"Northwestern University","biomarkers":" CD20 • CD5 • CD52 • FCER2","pipe":" | ","alterations":" CD19 expression","tags":["CD20 • CD5 • CD52 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Campath (alemtuzumab) • Arzerra (ofatumumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 06/01/2011","start_date":" 06/01/2011","primary_txt":" Primary completion: 08/17/2015","primary_completion_date":" 08/17/2015","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2024-03-27"},{"id":"c2957436-cc4b-46f1-b57e-c905761bf625","acronym":"","url":"https://clinicaltrials.gov/study/NCT02626715","created_at":"2021-01-18T12:45:57.284Z","updated_at":"2024-07-02T16:35:25.740Z","phase":"Phase 2","brief_title":"Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS","source_id_and_acronym":"NCT02626715","lead_sponsor":"Randy Windreich","biomarkers":" FLT3 • CD34","pipe":" | ","alterations":" FLT3 positive","tags":["FLT3 • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Campath (alemtuzumab) • melphalan • fludarabine IV • hydroxyurea • thiotepa • busulfan"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 09/04/2015","start_date":" 09/04/2015","primary_txt":" Primary completion: 04/12/2023","primary_completion_date":" 04/12/2023","study_txt":" Completion: 04/12/2023","study_completion_date":" 04/12/2023","last_update_posted":"2023-12-19"},{"id":"a06f8976-07ab-403a-b4d1-63d88700423a","acronym":"","url":"https://clinicaltrials.gov/study/NCT00074282","created_at":"2021-01-18T00:11:47.065Z","updated_at":"2024-07-02T16:35:44.331Z","phase":"Phase 2","brief_title":"Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL","source_id_and_acronym":"NCT00074282","lead_sponsor":"Eastern Cooperative Oncology Group","biomarkers":" CD5 • CD2","pipe":"","alterations":" ","tags":["CD5 • CD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • Campath (alemtuzumab) • pentostatin • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 102","initiation":"Initiation: 04/14/2005","start_date":" 04/14/2005","primary_txt":" Primary completion: 12/09/2017","primary_completion_date":" 12/09/2017","study_txt":" Completion: 05/06/2018","study_completion_date":" 05/06/2018","last_update_posted":"2023-06-29"},{"id":"f5563541-42ba-4928-8bc5-ee322d350ebf","acronym":"","url":"https://clinicaltrials.gov/study/NCT00199030","created_at":"2021-09-05T08:53:21.634Z","updated_at":"2024-07-02T16:35:52.983Z","phase":"Phase 2","brief_title":"Treatment of Relapsed T-cell Acute Lymphoblastic Leukemia or T-lymphoblastic Lymphoma With MabCampath","source_id_and_acronym":"NCT00199030","lead_sponsor":"Goethe University","biomarkers":" CD52","pipe":" | ","alterations":" CD52 expression","tags":["CD52"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD52 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Campath (alemtuzumab) • cladribine"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 02/01/2004","start_date":" 02/01/2004","primary_txt":" Primary completion: 04/01/2008","primary_completion_date":" 04/01/2008","study_txt":" Completion: 04/01/2008","study_completion_date":" 04/01/2008","last_update_posted":"2023-03-20"},{"id":"744723a9-90ed-4352-b528-1334c0f2bb39","acronym":"UCAML","url":"https://clinicaltrials.gov/study/NCT01247701","created_at":"2021-01-18T05:01:30.542Z","updated_at":"2024-07-02T16:36:09.213Z","phase":"","brief_title":"Umbilical Cord Blood Transplant for Children With Myeloid Hematological Malignancies","source_id_and_acronym":"NCT01247701 - UCAML","lead_sponsor":"Baylor College of Medicine","biomarkers":" HLA-DRB1","pipe":"","alterations":" ","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Campath (alemtuzumab) • fludarabine IV • busulfan • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 11/01/2010","start_date":" 11/01/2010","primary_txt":" Primary completion: 10/01/2019","primary_completion_date":" 10/01/2019","study_txt":" Completion: 10/01/2019","study_completion_date":" 10/01/2019","last_update_posted":"2022-06-08"},{"id":"6e4a9e4c-283b-45a8-92e3-5b41e4fbb313","acronym":"","url":"https://clinicaltrials.gov/study/NCT00345345","created_at":"2021-01-18T01:11:38.234Z","updated_at":"2024-07-02T16:36:11.133Z","phase":"Phase 2","brief_title":"Alemtuzumab (Campath) to Treat T-Large Granular Lymphocyte Leukemia","source_id_and_acronym":"NCT00345345","lead_sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","biomarkers":" CD8 • B3GAT1","pipe":"","alterations":" ","tags":["CD8 • B3GAT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Campath (alemtuzumab)"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 10/17/2006","start_date":" 10/17/2006","primary_txt":" Primary completion: 08/01/2017","primary_completion_date":" 08/01/2017","study_txt":" Completion: 10/27/2020","study_completion_date":" 10/27/2020","last_update_posted":"2022-05-03"},{"id":"d81c169d-027d-49d9-bff6-559eec0984c0","acronym":"","url":"https://clinicaltrials.gov/study/NCT00061945","created_at":"2021-09-05T08:53:17.801Z","updated_at":"2024-07-02T16:36:11.082Z","phase":"Phase 1/2","brief_title":"Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT00061945","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD52","pipe":"","alterations":" ","tags":["CD52"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • cytarabine • cyclophosphamide • Campath (alemtuzumab) • vincristine • daunorubicin • leucovorin calcium • mercaptopurine • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 302","initiation":"Initiation: 06/01/2003","start_date":" 06/01/2003","primary_txt":" Primary completion: 12/01/2007","primary_completion_date":" 12/01/2007","study_txt":" Completion: 10/01/2012","study_completion_date":" 10/01/2012","last_update_posted":"2022-05-03"},{"id":"c54753d7-1cf4-46f7-9de1-57a9fb61c4cb","acronym":"","url":"https://clinicaltrials.gov/study/NCT00951457","created_at":"2021-01-18T03:42:02.659Z","updated_at":"2024-07-02T16:36:16.114Z","phase":"Phase 1/2","brief_title":"Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL)","source_id_and_acronym":"NCT00951457","lead_sponsor":"Arbeitsgemeinschaft medikamentoese Tumortherapie","biomarkers":" CD38 • CD5 • FCER2","pipe":"","alterations":" ","tags":["CD38 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Campath (alemtuzumab) • bendamustine"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 03/01/2009","start_date":" 03/01/2009","primary_txt":" Primary completion: 08/06/2012","primary_completion_date":" 08/06/2012","study_txt":" Completion: 08/06/2012","study_completion_date":" 08/06/2012","last_update_posted":"2022-03-03"},{"id":"bd3cf553-3d2b-4a93-894b-9b071c94adb6","acronym":"","url":"https://clinicaltrials.gov/study/NCT00069238","created_at":"2021-01-18T00:10:21.560Z","updated_at":"2024-07-02T16:36:16.637Z","phase":"Phase 2","brief_title":"Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas","source_id_and_acronym":"NCT00069238","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ALK • CD52","pipe":" | ","alterations":" ALK positive • CD52 expression","tags":["ALK • CD52"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • CD52 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Campath (alemtuzumab) • vincristine • prednisone"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 09/19/2003","start_date":" 09/19/2003","primary_txt":" Primary completion: 06/11/2009","primary_completion_date":" 06/11/2009","study_txt":" Completion: 03/17/2021","study_completion_date":" 03/17/2021","last_update_posted":"2022-02-24"},{"id":"8f61df51-bc1b-4204-bd31-0fe890833aeb","acronym":"","url":"https://clinicaltrials.gov/study/NCT00858117","created_at":"2021-01-18T03:16:13.555Z","updated_at":"2025-02-25T17:17:10.767Z","phase":"Phase 2","brief_title":"A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL","source_id_and_acronym":"NCT00858117","lead_sponsor":"Northwestern University","biomarkers":" CD20 • CD5 • CD52 • CD2","pipe":" | ","alterations":" CD20 expression","tags":["CD20 • CD5 • CD52 • CD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Campath (alemtuzumab)"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 09/26/2005","start_date":" 09/26/2005","primary_txt":" Primary completion: 03/17/2010","primary_completion_date":" 03/17/2010","study_txt":" Completion: 01/24/2013","study_completion_date":" 01/24/2013","last_update_posted":"2020-11-06"},{"id":"e0854a67-8b83-41a5-a3f8-45934f25242c","acronym":"","url":"https://clinicaltrials.gov/study/NCT00536978","created_at":"2021-01-18T01:56:59.877Z","updated_at":"2024-07-02T16:36:40.726Z","phase":"Phase 2","brief_title":"Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies","source_id_and_acronym":"NCT00536978","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD20","pipe":" | ","alterations":" CD20 negative","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • cyclophosphamide • etoposide IV • Campath (alemtuzumab) • carmustine • melphalan • fludarabine IV • Depocyte (liposomal cytarabine) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 09/01/2007","start_date":" 09/01/2007","primary_txt":" Primary completion: 11/01/2010","primary_completion_date":" 11/01/2010","study_txt":" Completion: 11/01/2010","study_completion_date":" 11/01/2010","last_update_posted":"2020-09-24"},{"id":"dc88e68f-f782-4d5a-b32b-216a22465e77","acronym":"","url":"https://clinicaltrials.gov/study/NCT01269385","created_at":"2021-01-18T05:07:58.484Z","updated_at":"2024-07-02T16:36:43.905Z","phase":"Phase 1/2","brief_title":"Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia","source_id_and_acronym":"NCT01269385","lead_sponsor":"Mayo Clinic","biomarkers":" CD20 • CCND1 • IGH • CD38 • CD5 • FCER2","pipe":" | ","alterations":" CD38 expression • CD20 expression","tags":["CD20 • CCND1 • IGH • CD38 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD38 expression • CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Campath (alemtuzumab) • Imprime PGG (odetiglucan)"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 01/01/2011","start_date":" 01/01/2011","primary_txt":" Primary completion: 06/01/2014","primary_completion_date":" 06/01/2014","study_txt":" Completion: 06/01/2015","study_completion_date":" 06/01/2015","last_update_posted":"2020-06-23"},{"id":"f5f7e9e9-4884-4e93-8627-a995d1f87bfb","acronym":"","url":"https://clinicaltrials.gov/study/NCT00562328","created_at":"2021-01-18T02:02:58.656Z","updated_at":"2024-07-02T16:36:46.382Z","phase":"Phase 2","brief_title":"Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia","source_id_and_acronym":"NCT00562328","lead_sponsor":"Mayo Clinic","biomarkers":" CD20 • CCND1 • CD38 • CD5 • FCER2","pipe":" | ","alterations":" CD19 positive • CD38 expression • CD20 expression • CD5 positive","tags":["CD20 • CCND1 • CD38 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • CD38 expression • CD20 expression • CD5 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Campath (alemtuzumab) • Leukine (sargramostim)"],"overall_status":"Completed","enrollment":" Enrollment 33","initiation":"Initiation: 01/01/2008","start_date":" 01/01/2008","primary_txt":" Primary completion: 02/05/2010","primary_completion_date":" 02/05/2010","study_txt":" Completion: 12/18/2014","study_completion_date":" 12/18/2014","last_update_posted":"2020-04-08"},{"id":"19abf447-4689-4fc4-8eab-cc3dd49be351","acronym":"","url":"https://clinicaltrials.gov/study/NCT00040846","created_at":"2021-01-18T00:02:50.776Z","updated_at":"2024-07-02T16:36:50.764Z","phase":"Phase 2","brief_title":"Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies","source_id_and_acronym":"NCT00040846","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" CD33 • HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["CD33 • HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Campath (alemtuzumab) • fludarabine IV • cyclosporin A microemulsion"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 11/01/2001","start_date":" 11/01/2001","primary_txt":" Primary completion: 12/01/2009","primary_completion_date":" 12/01/2009","study_txt":" Completion: 12/01/2009","study_completion_date":" 12/01/2009","last_update_posted":"2020-01-29"},{"id":"328cfa69-77bc-4494-95a8-20ebcc13e19a","acronym":"","url":"https://clinicaltrials.gov/study/NCT00048412","created_at":"2021-01-18T00:04:44.960Z","updated_at":"2024-07-02T16:36:51.151Z","phase":"Phase 1/2","brief_title":"Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H","source_id_and_acronym":"NCT00048412","lead_sponsor":"Baylor College of Medicine","biomarkers":" HLA-DRB1","pipe":"","alterations":" ","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Campath (alemtuzumab) • fludarabine IV"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 06/01/2000","start_date":" 06/01/2000","primary_txt":" Primary completion: 11/12/2004","primary_completion_date":" 11/12/2004","study_txt":" Completion: 11/12/2004","study_completion_date":" 11/12/2004","last_update_posted":"2020-01-18"},{"id":"33e1da73-3fd8-41e5-b11d-9c4167b56563","acronym":"","url":"https://clinicaltrials.gov/study/NCT00085449","created_at":"2022-01-21T21:54:04.321Z","updated_at":"2024-07-02T16:36:53.140Z","phase":"Phase 1/2","brief_title":"Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer","source_id_and_acronym":"NCT00085449","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Campath (alemtuzumab) • melphalan • fludarabine IV • cyclosporine"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 05/01/2006","start_date":" 05/01/2006","primary_txt":" Primary completion: 01/01/2007","primary_completion_date":" 01/01/2007","study_txt":" Completion: 01/01/2007","study_completion_date":" 01/01/2007","last_update_posted":"2019-11-27"},{"id":"9c5e4e1e-d50a-4f40-aa00-425ef29cbd1a","acronym":"","url":"https://clinicaltrials.gov/study/NCT00520130","created_at":"2021-01-18T01:52:41.568Z","updated_at":"2024-07-02T16:37:02.230Z","phase":"Phase 2","brief_title":"Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System","source_id_and_acronym":"NCT00520130","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD8 • CD4 • CCR7 • IL7","pipe":"","alterations":" ","tags":["CD8 • CD4 • CCR7 • IL7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • Campath (alemtuzumab) • sirolimus • fludarabine IV • cyclosporin A microemulsion • Neupogen (filgrastim)"],"overall_status":"Completed","enrollment":" Enrollment 92","initiation":"Initiation: 10/30/2007","start_date":" 10/30/2007","primary_txt":" Primary completion: 10/14/2015","primary_completion_date":" 10/14/2015","study_txt":" Completion: 12/31/2018","study_completion_date":" 12/31/2018","last_update_posted":"2019-03-05"},{"id":"4878c545-1abc-40e1-850b-d27be0d5f377","acronym":"ACT-1","url":"https://clinicaltrials.gov/study/NCT00646854","created_at":"2021-01-18T02:24:24.264Z","updated_at":"2024-07-02T16:37:02.320Z","phase":"Phase 3","brief_title":"Alemtuzumab and CHOP in T-cell Lymphoma","source_id_and_acronym":"NCT00646854 - ACT-1","lead_sponsor":"Aarhus University Hospital","biomarkers":" CD34 • CD52","pipe":" | ","alterations":" CD34 positive • CD52 expression","tags":["CD34 • CD52"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD34 positive • CD52 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • Campath (alemtuzumab) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 136","initiation":"Initiation: 06/01/2008","start_date":" 06/01/2008","primary_txt":" Primary completion: 12/31/2016","primary_completion_date":" 12/31/2016","study_txt":" Completion: 12/31/2016","study_completion_date":" 12/31/2016","last_update_posted":"2019-03-01"},{"id":"4a2746eb-745d-49e4-9069-927f5f5fa497","acronym":"","url":"https://clinicaltrials.gov/study/NCT00565981","created_at":"2021-01-18T02:03:51.512Z","updated_at":"2025-02-25T15:57:23.642Z","phase":"Phase 2","brief_title":"A Pilot Trial With Subcutaneous Alemtuzumab and Oral Fludarabinephosphate for the Determination of Safety, Efficacy and Molecular Profiling for the Prediction of Response","source_id_and_acronym":"NCT00565981","lead_sponsor":"Arbeitsgemeinschaft medikamentoese Tumortherapie","biomarkers":" CD5 • FCER2","pipe":"","alterations":" ","tags":["CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Campath (alemtuzumab) • fludarabine IV"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 03/01/2004","start_date":" 03/01/2004","primary_txt":" Primary completion: 02/13/2008","primary_completion_date":" 02/13/2008","study_txt":" Completion: 02/13/2008","study_completion_date":" 02/13/2008","last_update_posted":"2017-12-07"},{"id":"1403ecda-4eb2-4815-a282-7d8e1f830b9f","acronym":"","url":"https://clinicaltrials.gov/study/NCT00301834","created_at":"2021-01-18T01:01:58.975Z","updated_at":"2024-07-02T16:37:17.471Z","phase":"Phase 2","brief_title":"Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders","source_id_and_acronym":"NCT00301834","lead_sponsor":"University of California, San Francisco","biomarkers":" CD34 • HLA-B","pipe":"","alterations":" ","tags":["CD34 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Campath (alemtuzumab) • fludarabine IV • busulfan • cyclosporine"],"overall_status":"Completed","enrollment":" Enrollment 35","initiation":"Initiation: 01/01/2005","start_date":" 01/01/2005","primary_txt":" Primary completion: 09/01/2011","primary_completion_date":" 09/01/2011","study_txt":" Completion: 09/01/2011","study_completion_date":" 09/01/2011","last_update_posted":"2017-09-28"},{"id":"d341898e-c40c-45c0-978e-227bf3b840f2","acronym":"","url":"https://clinicaltrials.gov/study/NCT00935792","created_at":"2021-01-18T03:37:37.975Z","updated_at":"2024-07-02T16:37:17.541Z","phase":"Phase 1/2","brief_title":"Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","source_id_and_acronym":"NCT00935792","lead_sponsor":"Mayo Clinic","biomarkers":" CD20 • CCND1 • CD5 • CD52 • FCER2","pipe":" | ","alterations":" CD20 expression • CD52 expression","tags":["CD20 • CCND1 • CD5 • CD52 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression • CD52 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Campath (alemtuzumab)"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 07/01/2009","start_date":" 07/01/2009","primary_txt":" Primary completion: 12/01/2015","primary_completion_date":" 12/01/2015","study_txt":" Completion: 12/01/2015","study_completion_date":" 12/01/2015","last_update_posted":"2017-09-26"},{"id":"4de7f334-1be6-452a-878d-44edcf23018e","acronym":"","url":"https://clinicaltrials.gov/study/NCT00118352","created_at":"2021-01-18T00:23:57.200Z","updated_at":"2024-07-02T16:37:21.595Z","phase":"Phase 2","brief_title":"Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer","source_id_and_acronym":"NCT00118352","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Campath (alemtuzumab) • fludarabine IV • cyclosporin A microemulsion"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 03/01/2005","start_date":" 03/01/2005","primary_txt":" Primary completion: 07/01/2010","primary_completion_date":" 07/01/2010","study_txt":" Completion: 05/26/2015","study_completion_date":" 05/26/2015","last_update_posted":"2017-05-30"},{"id":"55ef0201-4060-4b13-97b7-03d77f259381","acronym":"","url":"https://clinicaltrials.gov/study/NCT00323323","created_at":"2021-01-18T01:06:52.830Z","updated_at":"2025-02-25T17:14:14.461Z","phase":"Phase 1","brief_title":"CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas","source_id_and_acronym":"NCT00323323","lead_sponsor":"Ohio State University Comprehensive Cancer Center","biomarkers":" CD20","pipe":" | ","alterations":" CD20 negative","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • Campath (alemtuzumab) • vincristine • prednisone • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 03/01/2004","start_date":" 03/01/2004","primary_txt":" Primary completion: 08/01/2012","primary_completion_date":" 08/01/2012","study_txt":" Completion: 10/01/2016","study_completion_date":" 10/01/2016","last_update_posted":"2017-01-20"}]